

# Antineoplastic Drugs-Asia Pacific Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/A1B02F31B2EMEN.html>

Date: May 2018

Pages: 130

Price: US\$ 3,480.00 (Single User License)

ID: A1B02F31B2EMEN

## Abstracts

### Report Summary

Antineoplastic Drugs-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antineoplastic Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Asia Pacific and Regional Market Size of Antineoplastic Drugs 2013-2017, and development forecast 2018-2023

Main market players of Antineoplastic Drugs in Asia Pacific, with company and product introduction, position in the Antineoplastic Drugs market

Market status and development trend of Antineoplastic Drugs by types and applications

Cost and profit status of Antineoplastic Drugs, and marketing status

Market growth drivers and challenges

The report segments the Asia Pacific Antineoplastic Drugs market as:

Asia Pacific Antineoplastic Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

China

Japan

Korea

India

Southeast Asia

## Australia

Asia Pacific Antineoplastic Drugs Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Chemotherapeutic Agents  
Biological/Immunotherapeutic Agents  
Personalized Medicine

Asia Pacific Antineoplastic Drugs Market: Application Segment Analysis (Consumption  
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals  
Clinics  
Cancer Rehabilitation Centers  
Ambulatory Surgical Centers

Asia Pacific Antineoplastic Drugs Market: Players Segment Analysis (Company and  
Product introduction, Antineoplastic Drugs Sales Volume, Revenue, Price and Gross  
Margin):

Hoffmann-La Roche  
Amgen  
Bristol-Myers Squibb  
Baxter Healthcare  
Boehringer Ingelheim  
Aspen Global  
Bayer AG  
Teva pharmaceutical Industries  
Johnson & Johnson  
Merc & Co.  
Pfizer  
Accord Healthcare  
Genentech  
Lundbeck  
AbbVie

In a word, the report provides detailed statistics and analysis on the state of the  
industry; and is a valuable source of guidance and direction for companies and

individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF ANTINEOPLASTIC DRUGS**

- 1.1 Definition of Antineoplastic Drugs in This Report
- 1.2 Commercial Types of Antineoplastic Drugs
  - 1.2.1 Chemotherapeutic Agents
  - 1.2.2 Biological/Immunotherapeutic Agents
  - 1.2.3 Personalized Medicine
- 1.3 Downstream Application of Antineoplastic Drugs
  - 1.3.1 Hospitals
  - 1.3.2 Clinics
  - 1.3.3 Cancer Rehabilitation Centers
  - 1.3.4 Ambulatory Surgical Centers
- 1.4 Development History of Antineoplastic Drugs
- 1.5 Market Status and Trend of Antineoplastic Drugs 2013-2023
  - 1.5.1 China Antineoplastic Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional Antineoplastic Drugs Market Status and Trend 2013-2023

### **CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Antineoplastic Drugs in China 2013-2017
- 2.2 Consumption Market of Antineoplastic Drugs in China by Regions
  - 2.2.1 Consumption Volume of Antineoplastic Drugs in China by Regions
  - 2.2.2 Revenue of Antineoplastic Drugs in China by Regions
- 2.3 Market Analysis of Antineoplastic Drugs in China by Regions
  - 2.3.1 Market Analysis of Antineoplastic Drugs in North China 2013-2017
  - 2.3.2 Market Analysis of Antineoplastic Drugs in Northeast China 2013-2017
  - 2.3.3 Market Analysis of Antineoplastic Drugs in East China 2013-2017
  - 2.3.4 Market Analysis of Antineoplastic Drugs in Central & South China 2013-2017
  - 2.3.5 Market Analysis of Antineoplastic Drugs in Southwest China 2013-2017
  - 2.3.6 Market Analysis of Antineoplastic Drugs in Northwest China 2013-2017
- 2.4 Market Development Forecast of Antineoplastic Drugs in China 2018-2023
  - 2.4.1 Market Development Forecast of Antineoplastic Drugs in China 2018-2023
  - 2.4.2 Market Development Forecast of Antineoplastic Drugs by Regions 2018-2023

### **CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole China Market Status by Types

- 3.1.1 Consumption Volume of Antineoplastic Drugs in China by Types
- 3.1.2 Revenue of Antineoplastic Drugs in China by Types
- 3.2 China Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in North China
  - 3.2.2 Market Status by Types in Northeast China
  - 3.2.3 Market Status by Types in East China
  - 3.2.4 Market Status by Types in Central & South China
  - 3.2.5 Market Status by Types in Southwest China
  - 3.2.6 Market Status by Types in Northwest China
- 3.3 Market Forecast of Antineoplastic Drugs in China by Types

## **CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Antineoplastic Drugs in China by Downstream Industry
- 4.2 Demand Volume of Antineoplastic Drugs by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Antineoplastic Drugs by Downstream Industry in North China
  - 4.2.2 Demand Volume of Antineoplastic Drugs by Downstream Industry in Northeast China
  - 4.2.3 Demand Volume of Antineoplastic Drugs by Downstream Industry in East China
  - 4.2.4 Demand Volume of Antineoplastic Drugs by Downstream Industry in Central & South China
  - 4.2.5 Demand Volume of Antineoplastic Drugs by Downstream Industry in Southwest China
  - 4.2.6 Demand Volume of Antineoplastic Drugs by Downstream Industry in Northwest China
- 4.3 Market Forecast of Antineoplastic Drugs in China by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTINEOPLASTIC DRUGS**

- 5.1 China Economy Situation and Trend Overview
- 5.2 Antineoplastic Drugs Downstream Industry Situation and Trend Overview

## **CHAPTER 6 ANTINEOPLASTIC DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA**

- 6.1 Sales Volume of Antineoplastic Drugs in China by Major Players

- 6.2 Revenue of Antineoplastic Drugs in China by Major Players
- 6.3 Basic Information of Antineoplastic Drugs by Major Players
  - 6.3.1 Headquarters Location and Established Time of Antineoplastic Drugs Major Players
  - 6.3.2 Employees and Revenue Level of Antineoplastic Drugs Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 ANTINEOPLASTIC DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Hoffmann-La Roche
  - 7.1.1 Company profile
  - 7.1.2 Representative Antineoplastic Drugs Product
  - 7.1.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Hoffmann-La Roche
- 7.2 Amgen
  - 7.2.1 Company profile
  - 7.2.2 Representative Antineoplastic Drugs Product
  - 7.2.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Amgen
- 7.3 Bristol-Myers Squibb
  - 7.3.1 Company profile
  - 7.3.2 Representative Antineoplastic Drugs Product
  - 7.3.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
- 7.4 Baxter Healthcare
  - 7.4.1 Company profile
  - 7.4.2 Representative Antineoplastic Drugs Product
  - 7.4.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Baxter Healthcare
- 7.5 Boehringer Ingelheim
  - 7.5.1 Company profile
  - 7.5.2 Representative Antineoplastic Drugs Product
  - 7.5.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
- 7.6 Aspen Global
  - 7.6.1 Company profile

- 7.6.2 Representative Antineoplastic Drugs Product
- 7.6.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Aspen Global
- 7.7 Bayer AG
  - 7.7.1 Company profile
  - 7.7.2 Representative Antineoplastic Drugs Product
  - 7.7.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
- 7.8 Teva pharmaceutical Industries
  - 7.8.1 Company profile
  - 7.8.2 Representative Antineoplastic Drugs Product
  - 7.8.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Teva pharmaceutical Industries
- 7.9 Johnson & Johnson
  - 7.9.1 Company profile
  - 7.9.2 Representative Antineoplastic Drugs Product
  - 7.9.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.10 Merc & Co.
  - 7.10.1 Company profile
  - 7.10.2 Representative Antineoplastic Drugs Product
  - 7.10.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Merc & Co.
- 7.11 Pfize
  - 7.11.1 Company profile
  - 7.11.2 Representative Antineoplastic Drugs Product
  - 7.11.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Pfize
- 7.12 Accord Healthcare
  - 7.12.1 Company profile
  - 7.12.2 Representative Antineoplastic Drugs Product
  - 7.12.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Accord Healthcare
- 7.13 Genentech
  - 7.13.1 Company profile
  - 7.13.2 Representative Antineoplastic Drugs Product
  - 7.13.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Genentech
- 7.14 Lundbeck
  - 7.14.1 Company profile
  - 7.14.2 Representative Antineoplastic Drugs Product
  - 7.14.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of Lundbeck
- 7.15 AbbVie
  - 7.15.1 Company profile

- 7.15.2 Representative Antineoplastic Drugs Product
- 7.15.3 Antineoplastic Drugs Sales, Revenue, Price and Gross Margin of AbbVie

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTINEOPLASTIC DRUGS**

- 8.1 Industry Chain of Antineoplastic Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTINEOPLASTIC DRUGS**

- 9.1 Cost Structure Analysis of Antineoplastic Drugs
- 9.2 Raw Materials Cost Analysis of Antineoplastic Drugs
- 9.3 Labor Cost Analysis of Antineoplastic Drugs
- 9.4 Manufacturing Expenses Analysis of Antineoplastic Drugs

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTINEOPLASTIC DRUGS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source



- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Antineoplastic Drugs-Asia Pacific Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/A1B02F31B2EMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A1B02F31B2EMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970